EHA 2025 | Combining chemotherapy, brentuximab vedotin, and nivolumab in advanced-stage Hodgkin’s lymphoma

In our study in the EHA 2025 in Milan, we have presented a study, a Phase II study on high-risk patients with advanced stage Hodgkin’s disease. I mean a stage three and four disease with high score, IPI score, IPS score between two and three. So in this kind of patients, we have used the backbone treatment which is chemotherapy AVD and we have also used brentuximab vedotin, which is anti-CD30 and a combination with nivolumab which is a PD-L1 inhibitor. So we have included about 30 patients treated with AVD, brentuximab, nivolumab every 14 days for some of 12 cycles. After the end of the six cycles, we have evaluated other patients with PET-CT, demonstrating a complete metabolic response in 22 patients. And after the end of treatment, another six cycles have joined the complete responders to form 28 out of 30. The remaining two patients moved to high dose chemotherapy and autologous bone marrow transplant. After three years of follow-up, the progression-free survival was about 86% and the overall survival rate was 96%. After the five years of survival, which was presented today in Milan, has reached 80% as progression-free survival rate and 93% as overall survival. It remains to say that this combination showing that brentuximab vedotin as an anti-CD30 has a synergistic effect with the backbone chemotherapy, AVD, and nivolumab as a PD-L1 inhibitor can modulate the microenvironment of the tumor background through activation of cell-mediated immunity.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.